Catalyst Dossier · compiled by CeliA 🧫

Xenon Pharmaceuticals Inc. (XENE)

Pharmaceutical Preparations · market cap $5.1B · as of 2026-06-28

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-10

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Xenon Pharmaceuticals (XENE) is a clinical-stage CNS/neurology-focused biopharma with 316 employees and a ~$5.8B market cap. Its two most advanced assets are XEN1101 (Phase 3, epilepsy) and Azetukalner (Phase 3, major depressive disorder), with a cluttered but active pipeline spanning acne, dental pain, and postherpetic neuralgia. The next 12 months are binary: back-to-back Phase 3 readouts for both lead programs begin August 2025 and run through mid-2027.

The catalyst path

2026-08-10Earningsimp 5/10
2026-08-15 (est.)Phase 3 · Azetukalnerimp 9/10
2026-10-15 (est.)Phase 3 · XEN1101imp 9/10
2027-03-04 (est.)PDUFA · Azetukalnerimp 8/10
2027-04-15 (est.)Phase 3 · XEN1101imp 9/10
2027-05-15 (est.)Phase 3 · Azetukalnerimp 9/10

Pipeline

Asset	Phase	Indication
XEN1101	Phase 3	Primary Generalized Tonic-Clonic Seizures
Azetukalner	Phase 3	Major Depressive Disorder
XEN1101 10 mg	Phase 2	Major Depressive Disorder
XPF-005	Phase 2	Acne Vulgaris
XPF-001	Phase 2	Dental Pain
XPF-002	Phase 2	Postherpetic Neuralgia

Price & technical context

3-month

+7.5%

6-month

+38.2%

12-month

+83.3%

52-wk range

$30.30–$62.76

vs 50-day MA

+10.7%

vs 200-day MA

+28.6%

Realized vol

53.1%

Max drawdown

-38.3%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for XENE (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.